A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

Nimira Alimohamed; Jae Lyn Lee; Sandy Srinivas; Georg A. Bjarnason; Jennifer J. Knox; Mary J. Mackenzie; Lori Wood; Ulka N. Vaishampayan; Min Han Tan; Sun Young Rha; Frede Donskov; Srinivas Tantravahi; Christian Kollmannsberger; Scott North; Brian I. Rini; Toni K. Choueiri; Daniel Y.C. Heng

doi:10.1016/j.clgc.2013.12.003

A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

Nimira Alimohamed, Jae Lyn Lee, Sandy Srinivas, Georg A. Bjarnason, Jennifer J. Knox, Mary J. Mackenzie, Lori Wood, Ulka N. Vaishampayan, Min Han Tan, Sun Young Rha, Frede Donskov, Srinivas Tantravahi, Christian Kollmannsberger, Scott North, Brian I. Rini, Toni K. Choueiri, Daniel Y.C. Heng

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Background Several TTs are available to treat mRCC; however, the optimal sequence of therapy remains unknown. Patients and Methods Consecutive population-based samples of patients with mRCC treated with TT were collected from 12 cancer centers via the International Metastatic Renal Cell Carcinoma Database Consortium. Patient characteristics, first-line and second-line progression-free survival rates and overall survival data were collected based on sequencing of TT. Multivariable analysis was performed when there were significant differences on univariable analysis. Results A total of 2106 patients were included with a median follow-up of 36 months; 907 (43%) and 318 (15%) patients received subsequent second-line and third-line TT, respectively. Baseline characteristics were well matched among different sequences apart from more patients with non-clear-cell histology in the vascular endothelial growth factor (VEGF) to mammalian target of rapamycin (mTOR) group compared with the VEGF to VEGF group sequence. When adjusting for the Heng risk criteria and non-clear-cell histology, the hazard ratio for death for the VEGF to mTOR group versus the VEGF to VEGF group was 0.833 (95% confidence interval [CI], 0.669-1.037; P =.1016). More specifically, the adjusted hazard ratio for death for the sunitinib to everolimus versus sunitinib to temsirolimus sequences was 0.774 (95% CI, 0.52-1.153; P =.2086). Conclusion In this large multicenter analysis evaluating different sequences of TT in mRCC, no substantial effect on outcome based on sequence of TT was identified.

Original language	English
Pages (from-to)	e127-e131
Journal	Clinical Genitourinary Cancer
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/j.clgc.2013.12.003
Publication status	Published - 2014 Aug

Bibliographical note

Funding Information:
Jae-Lyn Lee has received honoraria from Novartis, Bayer, and Pfizer; has received research funding from Bayer. Georg A. Bjarnason has been a consultant and played an advisory role at Pfizer and received honoraria and research funding from Pfizer. Jennifer J. Knox has been a consultant and played an advisory role at Aveo and has received research funding from Pfizer. Mary J. MacKenzie has an advisory role and has received funding from Novartis and Pfizer. Lori Wood has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Ulka N. Vaishampayan has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Sun Young Rha has an advisory role at Novartis, Pfizer, and GlaxoSmithKline and has received research funding from Novartis and Bayer Korea. Frede Donskov has received research funding from Novartis. Christian Kollmannsberger has an advisory role and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Scott North has an advisory role at Novartis, Bayer, GlaxoSmithKline, and Pfizer. Brian I. Rini has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, and Onyx and has received research funding from GlaxoSmithKline and Pfizer. Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. Daniel Y.C. Heng has received research funding from Pfizer and has an advisory role at Pfizer, Novartis, GlaxoSmithKline, Aveo, Genentech, Bayer, and Onyx. All other authors state that they have no conflicts of interest.

All Science Journal Classification (ASJC) codes

Oncology
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clgc.2013.12.003

Cite this

Alimohamed, N., Lee, J. L., Srinivas, S., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., Wood, L., Vaishampayan, U. N., Tan, M. H., Rha, S. Y., Donskov, F., Tantravahi, S., Kollmannsberger, C., North, S., Rini, B. I., Choueiri, T. K., & Heng, D. Y. C. (2014). A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma. Clinical Genitourinary Cancer, 12(4), e127-e131. https://doi.org/10.1016/j.clgc.2013.12.003

@article{a1b94da01921467abf8bfbc33fb5fde2,

title = "A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma",

abstract = "Background Several TTs are available to treat mRCC; however, the optimal sequence of therapy remains unknown. Patients and Methods Consecutive population-based samples of patients with mRCC treated with TT were collected from 12 cancer centers via the International Metastatic Renal Cell Carcinoma Database Consortium. Patient characteristics, first-line and second-line progression-free survival rates and overall survival data were collected based on sequencing of TT. Multivariable analysis was performed when there were significant differences on univariable analysis. Results A total of 2106 patients were included with a median follow-up of 36 months; 907 (43%) and 318 (15%) patients received subsequent second-line and third-line TT, respectively. Baseline characteristics were well matched among different sequences apart from more patients with non-clear-cell histology in the vascular endothelial growth factor (VEGF) to mammalian target of rapamycin (mTOR) group compared with the VEGF to VEGF group sequence. When adjusting for the Heng risk criteria and non-clear-cell histology, the hazard ratio for death for the VEGF to mTOR group versus the VEGF to VEGF group was 0.833 (95% confidence interval [CI], 0.669-1.037; P =.1016). More specifically, the adjusted hazard ratio for death for the sunitinib to everolimus versus sunitinib to temsirolimus sequences was 0.774 (95% CI, 0.52-1.153; P =.2086). Conclusion In this large multicenter analysis evaluating different sequences of TT in mRCC, no substantial effect on outcome based on sequence of TT was identified.",

author = "Nimira Alimohamed and Lee, {Jae Lyn} and Sandy Srinivas and Bjarnason, {Georg A.} and Knox, {Jennifer J.} and Mackenzie, {Mary J.} and Lori Wood and Vaishampayan, {Ulka N.} and Tan, {Min Han} and Rha, {Sun Young} and Frede Donskov and Srinivas Tantravahi and Christian Kollmannsberger and Scott North and Rini, {Brian I.} and Choueiri, {Toni K.} and Heng, {Daniel Y.C.}",

note = "Funding Information: Jae-Lyn Lee has received honoraria from Novartis, Bayer, and Pfizer; has received research funding from Bayer. Georg A. Bjarnason has been a consultant and played an advisory role at Pfizer and received honoraria and research funding from Pfizer. Jennifer J. Knox has been a consultant and played an advisory role at Aveo and has received research funding from Pfizer. Mary J. MacKenzie has an advisory role and has received funding from Novartis and Pfizer. Lori Wood has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Ulka N. Vaishampayan has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Sun Young Rha has an advisory role at Novartis, Pfizer, and GlaxoSmithKline and has received research funding from Novartis and Bayer Korea. Frede Donskov has received research funding from Novartis. Christian Kollmannsberger has an advisory role and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Scott North has an advisory role at Novartis, Bayer, GlaxoSmithKline, and Pfizer. Brian I. Rini has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, and Onyx and has received research funding from GlaxoSmithKline and Pfizer. Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. Daniel Y.C. Heng has received research funding from Pfizer and has an advisory role at Pfizer, Novartis, GlaxoSmithKline, Aveo, Genentech, Bayer, and Onyx. All other authors state that they have no conflicts of interest.",

year = "2014",

month = aug,

doi = "10.1016/j.clgc.2013.12.003",

language = "English",

volume = "12",

pages = "e127--e131",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier",

number = "4",

}

Alimohamed, N, Lee, JL, Srinivas, S, Bjarnason, GA, Knox, JJ, Mackenzie, MJ, Wood, L, Vaishampayan, UN, Tan, MH, Rha, SY, Donskov, F, Tantravahi, S, Kollmannsberger, C, North, S, Rini, BI, Choueiri, TK & Heng, DYC 2014, 'A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma', Clinical Genitourinary Cancer, vol. 12, no. 4, pp. e127-e131. https://doi.org/10.1016/j.clgc.2013.12.003

TY - JOUR

T1 - A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

AU - Alimohamed, Nimira

AU - Lee, Jae Lyn

AU - Srinivas, Sandy

AU - Bjarnason, Georg A.

AU - Knox, Jennifer J.

AU - Mackenzie, Mary J.

AU - Wood, Lori

AU - Vaishampayan, Ulka N.

AU - Tan, Min Han

AU - Rha, Sun Young

AU - Donskov, Frede

AU - Tantravahi, Srinivas

AU - Kollmannsberger, Christian

AU - North, Scott

AU - Rini, Brian I.

AU - Choueiri, Toni K.

AU - Heng, Daniel Y.C.

N1 - Funding Information: Jae-Lyn Lee has received honoraria from Novartis, Bayer, and Pfizer; has received research funding from Bayer. Georg A. Bjarnason has been a consultant and played an advisory role at Pfizer and received honoraria and research funding from Pfizer. Jennifer J. Knox has been a consultant and played an advisory role at Aveo and has received research funding from Pfizer. Mary J. MacKenzie has an advisory role and has received funding from Novartis and Pfizer. Lori Wood has an advisory role at Pfizer and Novartis and has received research funding from Pfizer, Novartis, and GlaxoSmithKline. Ulka N. Vaishampayan has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Sun Young Rha has an advisory role at Novartis, Pfizer, and GlaxoSmithKline and has received research funding from Novartis and Bayer Korea. Frede Donskov has received research funding from Novartis. Christian Kollmannsberger has an advisory role and has received honoraria and research funding from Pfizer, Novartis, and GlaxoSmithKline. Scott North has an advisory role at Novartis, Bayer, GlaxoSmithKline, and Pfizer. Brian I. Rini has an advisory role at Pfizer, GlaxoSmithKline, Aveo, Bayer, and Onyx and has received research funding from GlaxoSmithKline and Pfizer. Toni K. Choueiri has received research funding from Pfizer and has an advisory role at Aveo, Pfizer, Novartis, GlaxoSmithKline, Genentech, Bayer, and Onyx. Daniel Y.C. Heng has received research funding from Pfizer and has an advisory role at Pfizer, Novartis, GlaxoSmithKline, Aveo, Genentech, Bayer, and Onyx. All other authors state that they have no conflicts of interest.

PY - 2014/8

Y1 - 2014/8

N2 - Background Several TTs are available to treat mRCC; however, the optimal sequence of therapy remains unknown. Patients and Methods Consecutive population-based samples of patients with mRCC treated with TT were collected from 12 cancer centers via the International Metastatic Renal Cell Carcinoma Database Consortium. Patient characteristics, first-line and second-line progression-free survival rates and overall survival data were collected based on sequencing of TT. Multivariable analysis was performed when there were significant differences on univariable analysis. Results A total of 2106 patients were included with a median follow-up of 36 months; 907 (43%) and 318 (15%) patients received subsequent second-line and third-line TT, respectively. Baseline characteristics were well matched among different sequences apart from more patients with non-clear-cell histology in the vascular endothelial growth factor (VEGF) to mammalian target of rapamycin (mTOR) group compared with the VEGF to VEGF group sequence. When adjusting for the Heng risk criteria and non-clear-cell histology, the hazard ratio for death for the VEGF to mTOR group versus the VEGF to VEGF group was 0.833 (95% confidence interval [CI], 0.669-1.037; P =.1016). More specifically, the adjusted hazard ratio for death for the sunitinib to everolimus versus sunitinib to temsirolimus sequences was 0.774 (95% CI, 0.52-1.153; P =.2086). Conclusion In this large multicenter analysis evaluating different sequences of TT in mRCC, no substantial effect on outcome based on sequence of TT was identified.

AB - Background Several TTs are available to treat mRCC; however, the optimal sequence of therapy remains unknown. Patients and Methods Consecutive population-based samples of patients with mRCC treated with TT were collected from 12 cancer centers via the International Metastatic Renal Cell Carcinoma Database Consortium. Patient characteristics, first-line and second-line progression-free survival rates and overall survival data were collected based on sequencing of TT. Multivariable analysis was performed when there were significant differences on univariable analysis. Results A total of 2106 patients were included with a median follow-up of 36 months; 907 (43%) and 318 (15%) patients received subsequent second-line and third-line TT, respectively. Baseline characteristics were well matched among different sequences apart from more patients with non-clear-cell histology in the vascular endothelial growth factor (VEGF) to mammalian target of rapamycin (mTOR) group compared with the VEGF to VEGF group sequence. When adjusting for the Heng risk criteria and non-clear-cell histology, the hazard ratio for death for the VEGF to mTOR group versus the VEGF to VEGF group was 0.833 (95% confidence interval [CI], 0.669-1.037; P =.1016). More specifically, the adjusted hazard ratio for death for the sunitinib to everolimus versus sunitinib to temsirolimus sequences was 0.774 (95% CI, 0.52-1.153; P =.2086). Conclusion In this large multicenter analysis evaluating different sequences of TT in mRCC, no substantial effect on outcome based on sequence of TT was identified.

UR - http://www.scopus.com/inward/record.url?scp=84904723067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904723067&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2013.12.003

DO - 10.1016/j.clgc.2013.12.003

M3 - Article

C2 - 24485801

AN - SCOPUS:84904723067

SN - 1558-7673

VL - 12

SP - e127-e131

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 4

ER -

A population-based overview of sequences of targeted therapy in Metastatic renal cell carcinoma

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this